Table 1.
Baseline characteristics.
Figure 1.
Changes in chemerin serum levels 16 weeks after initiation of treatment with adalimumab.
(A) Absolute change in all patients (n = 49). Data are represented as mean values with standard deviation. (B) Relative change for all patients (n = 49), EULAR responders (n = 38) and EULAR non- responders (n = 11). Data are presented as mean values with standard deviation.
Figure 2.
Changes in chemerin serum levels 16 weeks after initiation of treatment correlate with changes in disease activity parameters DAS28 (A, n = 49), ESR (B, n = 49) and CRP (C, n = 49) and changes in IL-6 (D, n = 29) and MIF (E, n = 41) serum levels, respectively.
Figure 3.
Chemerin levels at baseline tend to be higher in current smokers (n = 11) than in non-smokers (n = 38).
Data are presented as median values.